Scholars Central

Conference abstractPublished 5 Aug 2013

The immune system contributes to the treatment with nanotherapeutics

Authors: Rihova Blanka

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

N-(2-hydroxypropyl) methacrylamide (HPMA)-based copolymers containing doxorubicin or taxanes exert in vivo dual cytostatic and immunostimulating activity. The treatment regularly triggers systemic specific anticancer resistance that protects mice from a second cancer attack. Such therapy-inducible auto vaccination is dose and time dependent. More aggressive treatment which facilitates very rapid elimination of antigen/tumor cells induces low or even undetectable tumor resistance, whereas a slow eradication of tumor mass induces a strong tumor resistance. As proven by neutralization Winn?s test, the chief mediators of the phenomenon are CD8 + cytotoxic T lymphocytes (CTL) and memory cells. Mice suffering from acute tumor model responded to the therapy much better if compared with mice suffering from chronic tumor model. Such treatment- triggered cancer resistance could be explained by immunoprotective character of macromolecular therapeutics and their ability to induce immunogenic cancer cell death. We have detected in mouse EL4 T cell lymphoma exposed to DOX-HPMA translocation of calreticulin, ERp57 and HSPs (60, 70, 90, and 110) and release of high-mobility-group box 1 protein (HMGB1). Moreover, in vitro treatment of EL4 and mouse B cell lymphoma 38C13 increases phagocytosis by dendritic cells while engulfment of similarly treated normal cell is not enhanced due to high expression of CD47. Mice treated with ?immunosafe? polymeric conjugates showed significantly lower cancer cell infiltration in inguinal (ipsilateral) lymph nodes if compared to mice treated with free doxorubicin.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Translational Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalTranslational Medicine
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Rihova Blanka”